10-Q: Lifeway Foods Achieves Record Q2 Sales, Strong Growth

Lifeway Foods reported record second-quarter net sales of $53.9 million, driven by strong volume growth in its core kefir products and significant gross margin expansion.

Summary

• Achieved record net sales of $53.9 million for the second quarter ended June 30, 2025, a 9.7% increase year-over-year.
• Comparable net sales, adjusting for a strategically exited customer relationship and a distributor shift, increased approximately 18% in Q2 2025.
• Gross profit margin expanded to 28.6% in Q2 2025, up from 27.0% in the prior year, driven by higher branded product volumes and manufacturing efficiencies.
• Net income for Q2 2025 was $4.2 million, resulting in diluted EPS of $0.28, compared to $3.8 million and $0.25 diluted EPS in Q2 2024.
• Year-to-date net sales reached $99.99 million, a 6.6% increase, with comparable net sales up approximately 14%.
• Net income for the six months ended June 30, 2025, was $7.79 million, up from $6.21 million in the prior year.
• Cash and cash equivalents increased to $21.22 million as of June 30, 2025, from $16.73 million at December 31, 2024.
• Liquidation of an equity investment in Simple Mills generated $5.21 million in cash proceeds and a $3.41 million gain.
• Increased the revolving credit facility commitment from $5 million to $25 million, extending the termination date to February 5, 2028, with no outstanding borrowings as of June 30, 2025.
• Initiated a strategic move to secure organic milk supply by purchasing 224 mature dairy cows for $694 thousand in July 2025, with plans for third-party management and a supply agreement with a COOP.

Sentiment

Score: 9

Explanation: The company reported record sales, significant gross margin expansion, and strong profitability growth. Management's commentary is highly optimistic, highlighting continued momentum, strategic initiatives for supply chain control, and industry recognition. The increased credit facility provides ample liquidity, and the long-term Adjusted EBITDA target is ambitious. The only minor negative is the decrease in operating cash flow, but this is offset by strong net income and strategic asset sales.

Positives

• Record net sales of $53.9 million in Q2 2025, the highest quarter ever.
• Strong volume-led growth across the core portfolio, with comparable net sales increasing approximately 18% in Q2 2025 and 14% year-to-date.
• Significant gross profit margin expansion to 28.6% in Q2 2025, up 160 basis points year-over-year and over 460 basis points sequentially.
• Double-digit net income and diluted EPS growth year-over-year in Q2 2025.
• Strong cash position with cash and cash equivalents increasing to $21.22 million.
• Successful liquidation of Simple Mills investment, generating $5.21 million in cash and a $3.41 million gain.
• Expanded revolving credit facility to $25 million, providing significant liquidity for future borrowings.
• Strong momentum continuing into Q3 2025, with unaudited net sales up over 20% year-over-year through August 11, 2025.
• Achieved the highest single week of gross sales in company history in July 2025, surpassing $5.5 million.
• Recognized as 'Processor of the Year' by Dairy Foods magazine in July 2025.
• Successful product innovation with Probiotic Smoothies with Collagen, winning a 2025 Good Housekeeping Snack Award.

Negatives

• Selling expenses increased by $1.14 million in Q2 2025 and $2.14 million year-to-date, primarily due to increased marketing activities.
• General and administrative expenses increased by $575 thousand in Q2 2025 and $1.07 million year-to-date, driven by professional fees associated with non-routine stockholder action and the Danone unsolicited purchase proposal.
• Net cash provided by operating activities decreased to $3.76 million for the six months ended June 30, 2025, from $8.09 million in the same period of 2024, primarily due to lower cash earnings and changes in working capital.
• Unfavorable organic milk pricing partially offset the benefits of conventional milk pricing on gross profit.

Risks

• Changes in the pricing of commodities, including milk.
• Actions and decisions of competitors and customers, including those related to price competition.
• Ability to successfully implement business strategy.
• Effects of government regulation.
• Disruptions to the supply chain, or manufacturing and distribution capabilities, including those due to cybersecurity threats.
• Adverse economic conditions in the United States, the primary market, or any other jurisdictions where significant business is conducted, and resultant changes in consumer spending.
• Uncertainty regarding proposals or other actions taken by shareholders related to the unsolicited proposal made by Danone North America PBC to acquire shares.
• Potential for material adverse effects from legal proceedings, claims, disputes, regulatory matters, audits, and proceedings if ultimate resolution requires significant payments.

Future Outlook

The company reiterates its long-term target of $45-$50 million in Adjusted EBITDA for fiscal year 2027 and expresses confidence in delivering the strongest annual sales in company history in 2025. Momentum has carried into the second half of the year, with unaudited net sales for Q3 to date through August 11, 2025, reaching $26.4 million, an increase of over 20% compared to the same period last year. The company expects the accelerating consumer focus on health and wellness to drive increased demand for its products and does not currently anticipate macroeconomic conditions to have a material adverse impact on operations or financial results.

Management Comments

• "This was another quarter that reinforces Lifeway’s position as the undisputed leader in the kefir category."
• "We delivered $53.9 million in net sales, our highest quarter ever, with strong, volume-led growth across our core portfolio."
• "The consistency of our performance, even as we cycle past previous record highs, speaks to the strength of our brand, the loyalty of our customers, and the expanding reach of our platform."
• "Beyond topline growth, we expanded gross margin by 160 basis points year-over-year and more than 460 basis points sequentially, translating into double-digit net income and diluted EPS growth year-over-year."
• "We are executing with discipline while capturing powerful consumer tailwinds — from the continued wellness boom to the surge in GLP-1 medication use — as more people seek nutrient-dense, protein-rich, probiotic foods that support digestion, satiety, and natural GLP-1 hormone production."
• "Earning this award is a testament to our team’s dedication and to the role Lifeway has played in pioneering kefir in the U.S. for nearly 40 years."
• "We are just getting started. With record sales, expanding margins, category-leading innovation, and a production platform ready to scale, Lifeway is positioned for sustained, profitable growth. The best is yet to come."

Industry Context

The company operates within the growing health and wellness sector, particularly benefiting from increasing consumer demand for probiotic-based and nutrient-dense foods. Management specifically notes tailwinds from the 'continued wellness boom' and the 'surge in GLP-1 medication use,' which drives demand for protein-rich, probiotic foods supporting digestion and satiety. The company's focus on kefir positions it well within the fermented foods segment, and its innovation with products like Probiotic Smoothies with Collagen aligns with broader trends in functional foods and beauty-from-within categories.

Comparison to Industry Standards

• Lifeway Foods is the largest producer and marketer of kefir in the U.S., indicating a dominant market position within its core product category.
• The company was named 'Processor of the Year' by Dairy Foods magazine in July 2025, recognizing its innovation, leadership, growth, and impact on the dairy industry, suggesting strong performance relative to industry peers.
• The unsolicited purchase proposal from Danone North America PBC, a major global food company, highlights the strategic value and potential for consolidation within the dairy and probiotic sectors, implicitly comparing Lifeway's valuation and market position to larger industry players.

Corporate Governance

Legal Proceedings

• The company may be involved in various legal proceedings, claims, disputes, regulatory matters, audits, and proceedings arising in the ordinary course of business.
• Accruals for outstanding legal matters are not material individually or in the aggregate to the financial position.
• Management believes the ultimate resolution of these matters will not have a material adverse effect on the business, financial condition, results of operations, or cash flows, though it is possible such a contingency could have a material adverse effect if required to make payments.

Stakeholder Impact

• **Shareholders:** Positive impact due to record sales, increased profitability, strong EPS growth, and a positive future outlook. The Shareholder Rights Plan aims to protect their interests against unsolicited takeover bids.
• **Employees:** Continued investment in marketing and operations supports job stability and growth. Stock-based compensation and defined contribution plan contributions provide benefits.
• **Customers:** Benefit from continued product innovation (e.g., Probiotic Smoothies with Collagen) and increased availability of products due to strategic investments in milk supply.
• **Suppliers:** The strategic initiative to purchase dairy cows and enter into agreements with a third-party dairy and a COOP indicates a commitment to securing raw material supply, potentially strengthening relationships with agricultural suppliers.
• **Creditors:** The company's strong financial position, compliance with debt covenants, and increased revolving credit facility demonstrate robust liquidity and ability to meet obligations.

Next Steps

• Consider further mature dairy cow purchases in the future to increase organic milk supply.
• Assess the appropriate accounting treatment for the purchase of the herd and the agreement with the third-party Dairy.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial position, though no material impact is currently expected for the current fiscal year.
• Deliver the strongest annual sales in company history in 2025.
• Work towards the long-term target of $45-$50 million in Adjusted EBITDA for FY 2027.

Key Dates

Recommendation

The company demonstrates exceptional financial performance with record sales, significant gross margin expansion, and double-digit net income and EPS growth. The strong momentum is expected to continue into the next quarter, with management projecting the strongest annual sales in company history for 2025 and an ambitious long-term Adjusted EBITDA target. Strategic initiatives, such as securing organic milk supply and expanding the credit facility, enhance operational stability and liquidity. Despite increased operating expenses, the underlying business strength, market leadership in kefir, and positive industry trends (health and wellness, GLP-1) position Lifeway Foods for sustained profitable growth. The unsolicited Danone proposal also highlights potential strategic value.

Keywords

Kefir, Probiotic, Dairy, Fermented Foods, LWAY, Organic Milk, Consumer Goods, Food & Beverage, Healthy Eating, Financial Results